scholarly journals Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients

2012 ◽  
Vol 27 (7) ◽  
pp. 2971-2979 ◽  
Author(s):  
M. S. Sampaio ◽  
Y. W. Cho ◽  
T. Shah ◽  
S. Bunnapradist ◽  
I. V. Hutchinson
Keyword(s):  
Kidney Transplant ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Post Transplant ◽  
Barr Virus ◽  
Epstein Barr

Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients

2019 ◽  
Vol 29 (2) ◽  
pp. 185-193 ◽  
Author(s):  
Michelle Liu ◽  
Shahid Husain ◽  
Olusegun Famure ◽  
Yanhong Li ◽  
S. Joseph Kim
Keyword(s):  
Risk Factors ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Transplant Recipients ◽  
Posttransplant Lymphoproliferative Disorder ◽  
Kidney Transplant Recipients ◽  
Barr Virus ◽  
Incidence Risk ◽  
Epstein Barr

Background: Posttransplant lymphoproliferative disorder (PTLD) is a severe complication after kidney transplantation. This study examined the incidence, risk factors, clinical management, and outcomes of PTLD in a cohort of kidney transplant recipients. Design: This single-center cohort study included 1642 patients transplanted from January 1, 2000, to December 31, 2012, with follow-up until December 31, 2013. The incidence and risk factors for PTLD were examined using a Cox proportional hazards model. A Cox model was also used to assess the association of PTLD and graft outcomes. Results: Sixteen recipients developed PTLD over follow-up. The incidence rate was 0.18 (95% confidence interval [CI]: 0.11-0.29) cases per 100 person-years. Four were from Epstein–Barr virus (EBV) mismatched (D+/R−) transplants and 12 from EBV-positive recipients (R+). Recipients with D+/R− matches were at a significantly higher risk of developing PTLD than R+ (hazard ratio [HR]: 7.52 [95% CI: 2.42-23.32]). Fifteen cases had immunosuppression reduced, 11 cases were supplemented with rituximab or ganciclovir, 6 cases required chemotherapy or radiation, and 6 cases had tumors excised. By the end of follow-up, 6 patients went into remission, 5 returned to chronic dialysis, and 5 patients died. Patients with PTLD were significantly more likely to have total graft failure (return to chronic dialysis, preemptive retransplant, or death with graft function) than patients without PTLD (HR: 3.41 [95% CI: 1.72-6.78). Discussion: Epstein–Barr virus mismatch continues to be a strong risk factor for developing PTLD after kidney transplantation. Recipients with PTLD have a poor prognosis, as the optimal management remains to be elucidated.

scholarly journals TNF-α Production by Monocytes Stimulated With Epstein-Barr Virus–Peptides as a Marker of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients

2019 ◽  
Vol 4 (10) ◽  
pp. 1446-1453 ◽  
Author(s):  
François Bouchard-Boivin ◽  
Olivier Désy ◽  
Stéphanie Béland ◽  
Isabelle Houde ◽  
Sacha A. De Serres
Keyword(s):  
Adverse Events ◽  
Kidney Transplant ◽  
Epstein Barr Virus ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Barr Virus ◽  
Tnf Α ◽  
Epstein Barr

scholarly journals Asymptomatic Epstein-Barr virus shedding in the urine of kidney transplant recipients: case reports and review of the literature

2017 ◽  
Vol 8 (4) ◽  
Author(s):  
Maryam Rahbar ◽  
Gholamreza Poormand ◽  
Masoud Karkhaneh Mahmoodi ◽  
Aboozar Jazayeri ◽  
Seyed Mohammad Jazayeri
Keyword(s):  
Kidney Transplant ◽  
Epstein Barr Virus ◽  
Case Reports ◽  
Effector Memory ◽  
Transplant Recipients ◽  
Post Transplant ◽  
Barr Virus ◽  
Wide Range ◽  
Epstein Barr ◽  
Prospective Longitudinal

Epstein-Barr virus (EBV) is associated with a wide range of malignancies and complications like post-transplant lymphoproliferative disorder (PTLD). To suppress active EBV infection in transplant recipients, who are at a heightened risk of developing PTLD, EBV DNAemia monitoring has been recommended. Quantitative multiplex real time polymerase chain reaction (QMRTPCR) offered the advantage of detection of more than one target in the same sample. We present four cases of kidney transplant recipient who were admitted for rising serum creatinine between 9 and 20 months post-transplant with a suspicion of BKV-associated nephropathy. All but one patient had unusual sonography findings in their genitourinary tracts and were positive for urinary culture for bacteria. Using a commercial QMRTPCR that could detect and quantitate BKV, EBV and cytomegalovirus simultaneously, all patients were positive for EBV in their urine for the levels between 2500 and 8×108 U/mL. None of the patients had any symptoms regarding this finding. On following up survey 3 month post discharge from hospital, all patients were negative for plasma and urine EBV. Absent of EBV DNAemia together with alternating phases of detectable EBV in urine might reflect the presence of functionally efficient central/effector memory T cells against EBV. The significance of this finding in immunocompromized patients necessitates prospective longitudinal studies.

Sign in / Sign up

Export Citation Format

Share Document